Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: A relationship with disease subtype and clinical outcome

British Journal of Haematology

Volumn 93, Issue 1, 1996, Pages 45-52

  Ogata, Kiyoyuki ^a   Yokose, Norio ^a   An, Emi ^a   Kamikubo, Keiko ^a   Tamura, Hideto ^a   Dan, Kazuo ^a   Sakamaki, Hisashi ^b   Onozawa, Yasusuke ^b   Hamaguchi, Hiroyuki ^c   Nomura, Takeo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

clinical outcome; myelodysplastic syndromes; soluble interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECEPTORS, INTERLEUKIN-2;

EID: 9244232852     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.4641003.x     Document Type: Article

References (27)

1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Annals of Internal Medicine, 103, 626-629.
3. Foucar, K., Langdon, R.M., Armitage, J.O., Olson, D.B. & Carroll, T.J., Jr (1985) Myelodysplastic syndromes: a clinical and pathologic analysis of 109 cases. Cancer, 56, 553-561.
4. Garcia-Penarrubia, P., Koster, F.T., Kelley, R.O., McDowell, T.D. & Bankhurst, A.D. (1989) Antibacterial activity of human natural killer cells. Journal of Experimental Medicine, 169, 99-113.
5. Haller, O., Hansson, M., Kiessling, R. & Wigzell, H. (1977) Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature, 270, 609-611.
6. Hamaguchi, H., Takano, N., Saito, K., Enokihara, H., Furusawa, S. & Shishido, H. (1990) Interaction of monocytes and T cells in the regulation of normal human megakaryocytopoiesis in vitro: role of IL-1 and IL-2. British Journal of Haematology, 76, 12-20.
7. Herberman, R.B. (1992) Tumor immunology. Journal of the American Medical Association, 268, 2935-2939.
8. Hogan, P.G. & Basten, A. (1988) What are killer cells and what do they do? Blood Reviews, 2, 50-58.
9. Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E., Schulman, P., Itri, L., Gunter, P. & Besa, E. (1988) Randomized study of 1 3-cis retinoic acid v placebo in the myelodysplastic disorders. Blood, 71, 703-708.
10. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425-433.
11. Musilova, J. & Michalova, K. (1988) Chromosome study of 85 patients with myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 33, 39-50.
12. Negrin, R.S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S. & Greenberg, P.L. (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737-743.
13. Ogata, K., Yamada, T., Ito, T., Gomi, S., Tanabe, Y., Ohki, I., Dan, K. & Nomura, T. (1992) Low-dose etoposide: a potential therapy for myelodysplastic syndromes. British Journal of Haematology, 82, 354-357.
14. Pistoia, V., Ghio, R., Nocera, A., Leprini, A., Perata, A. & Ferrarini, M. (1985) Large granular lymphocytes have a promoting activity on human peripheral blood erythroid burst-forming units. Blood, 65, 464-472.
15. Pomeroy, C., Oken, M.M., Rydell, R.E. & Filice, G.A. (1991) Infection in the myelodysplastic syndromes. American Journal of Medicine, 90, 338-344.
16. Robertson, M.J. & Ritz, J. (1990) Biology and clinical relevance of human natural killer cells. Blood, 76, 2421-2438.
17. Rubin, L.A., Jay, G. & Nelson, D.L. (1986) The released interleukin 2 receptor binds interleukin 2 efficiently. Journal of Immunology, 137, 3841-3844.
18. Rubin, L.A. & Nelson, D.L. (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Annals of Internal Medicine, 113, 619-627.
19. Sanz, G.F., Sanz, M.A., Vallespi, T., Canizo, M.C., Torrabadella, M., Garcia, S., Irriguible, D. & Miguel, J.F.S. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-408.
20. Shibuya, T., Harada, M., Taniguchi, S., Okamura, T., Okamura, S. & Niho, Y. (1990) Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin. Leukemia Research, 14, 161-167.
21. Symons, J.A., Wood, N.C., Di Giovine, F.S. & Duff, G.W. (1988) Soluble IL-2 receptor in rheumatoid arthritis, correlation with disease activity, IL-1 and IL-2 inhibition. Journal of Immunology, 141, 2612-2618.
22. Tricot, G.J. (1992) Prognostic factors in the myelodysplastic syndromes. Leukemia Research, 16, 109-115.
23. Tricot, G., Vlietinck, R., Boogaerts, M.A., Hendrickx, B., De Wolf-Peeters, C., Van den Berghe, H. & Verwilghen, R.L. (1985) Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood cell counts, bone marrow cytology, trephine biopsy and chromosomal analysis. British Journal of Haematology, 60, 19-32.
24. Vallespi, T., Torrabadella, M., Julia, A., Irriguible, D., Jaen, A., Acebedo, G. & Triginer, J. (1985) Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. British Journal of Haematology, 61, 83-92.
25. + T-cells in myelodysplastic syndromes. Leukemia Research, 18, 777-782.
26. Yunis, J.J., Lobell, M., Arnesen, M.A., Oken, M.M., Mayer, M.G., Rydell, R.E. & Brunning, R.D. (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. British Journal of Haematology, 68, 189-194.
27. Zwierzina, H., Herold, M., Schollenberger, S., Geissler, D. & Schmalzl, F. (1991) Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. British Journal of Haematology, 79, 438-443.